254 related articles for article (PubMed ID: 26586007)
1. Atypical clinical and radiological course of a patient with Canavan disease.
Sarret C; Boespflug-Tanguy O; Rodriguez D
Metab Brain Dis; 2016 Apr; 31(2):475-9. PubMed ID: 26586007
[TBL] [Abstract][Full Text] [Related]
2. A mutation of aspartoacylase gene in a Turkish patient with Canavan disease.
Eke GH; Iscan A; Cece H; Calik M
Genet Couns; 2012; 23(1):9-12. PubMed ID: 22611636
[TBL] [Abstract][Full Text] [Related]
3. Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy.
von Jonquieres G; Spencer ZHT; Rowlands BD; Klugmann CB; Bongers A; Harasta AE; Parley KE; Cederholm J; Teahan O; Pickford R; Delerue F; Ittner LM; Fröhlich D; McLean CA; Don AS; Schneider M; Housley GD; Rae CD; Klugmann M
Acta Neuropathol; 2018 Jan; 135(1):95-113. PubMed ID: 29116375
[TBL] [Abstract][Full Text] [Related]
4. N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS; Wojtas I; Markov V; Gray SJ; McCown TJ; Samulski RJ; Bilaniuk LT; Wang DJ; De Vivo DC; Janson CG; Leone P
Neurobiol Dis; 2016 Dec; 96():323-334. PubMed ID: 27717881
[TBL] [Abstract][Full Text] [Related]
5. Atypical MRI findings in Canavan disease: a patient with a mild course.
Yalcinkaya C; Benbir G; Salomons GS; Karaarslan E; Rolland MO; Jakobs C; van der Knaap MS
Neuropediatrics; 2005 Oct; 36(5):336-9. PubMed ID: 16217711
[TBL] [Abstract][Full Text] [Related]
6. New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion.
Di Pietro V; Cavallari U; Amorini AM; Lazzarino G; Longo S; Poggiani C; Cavalli P; Tavazzi B
Clin Biochem; 2013 Dec; 46(18):1902-4. PubMed ID: 24036223
[TBL] [Abstract][Full Text] [Related]
7. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain.
Janson C; McPhee S; Bilaniuk L; Haselgrove J; Testaiuti M; Freese A; Wang DJ; Shera D; Hurh P; Rupin J; Saslow E; Goldfarb O; Goldberg M; Larijani G; Sharrar W; Liouterman L; Camp A; Kolodny E; Samulski J; Leone P
Hum Gene Ther; 2002 Jul; 13(11):1391-412. PubMed ID: 12162821
[TBL] [Abstract][Full Text] [Related]
8. Magnetic resonance imaging in juvenile Canavan disease.
Toft PB; Geiss-Holtorff R; Rolland MO; Pryds O; Müller-Forell W; Christensen E; Lehnert W; Lou HC; Ott D; Hennig J
Eur J Pediatr; 1993 Sep; 152(9):750-3. PubMed ID: 8223809
[TBL] [Abstract][Full Text] [Related]
9. N-Acetylaspartate Synthase Deficiency Corrects the Myelin Phenotype in a Canavan Disease Mouse Model But Does Not Affect Survival Time.
Maier H; Wang-Eckhardt L; Hartmann D; Gieselmann V; Eckhardt M
J Neurosci; 2015 Oct; 35(43):14501-16. PubMed ID: 26511242
[TBL] [Abstract][Full Text] [Related]
10. [Canavan disease or N-acetyl aspartic aciduria: a case report].
Boughamoura L; Chaabane F; Tilouche S; Chabchoub I; Kabachi N; Tlili K; Yacoub M; Essoussi AS
Arch Pediatr; 2007 Feb; 14(2):173-6. PubMed ID: 17196380
[TBL] [Abstract][Full Text] [Related]
11. Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease.
Matalon R; Surendran S; Rady PL; Quast MJ; Campbell GA; Matalon KM; Tyring SK; Wei J; Peden CS; Ezell EL; Muzyczka N; Mandel RJ
Mol Ther; 2003 May; 7(5 Pt 1):580-7. PubMed ID: 12718900
[TBL] [Abstract][Full Text] [Related]
12. Natural history of Canavan disease revealed by proton magnetic resonance spectroscopy (1H-MRS) and diffusion-weighted MRI.
Janson CG; McPhee SW; Francis J; Shera D; Assadi M; Freese A; Hurh P; Haselgrove J; Wang DJ; Bilaniuk L; Leone P
Neuropediatrics; 2006 Aug; 37(4):209-21. PubMed ID: 17177147
[TBL] [Abstract][Full Text] [Related]
13. Restoration of aspartoacylase activity in CNS neurons does not ameliorate motor deficits and demyelination in a model of Canavan disease.
Klugmann M; Leichtlein CB; Symes CW; Serikawa T; Young D; During MJ
Mol Ther; 2005 May; 11(5):745-53. PubMed ID: 15851013
[TBL] [Abstract][Full Text] [Related]
14. NAAG synthetase deficiency has only low influence on pathogenesis in a Canavan disease mouse model.
Becker I; Wang-Eckhardt L; Eckhardt M
J Inherit Metab Dis; 2024 Mar; 47(2):230-243. PubMed ID: 38011891
[TBL] [Abstract][Full Text] [Related]
15. Leukodystrophy with multiple beaded periventricular cysts: unusual cranial MRI results in Canavan disease.
Drenckhahn A; Schuelke M; Knierim E
J Inherit Metab Dis; 2015 Sep; 38(5):983-4. PubMed ID: 25647544
[TBL] [Abstract][Full Text] [Related]
16. Novel mutation in an Egyptian patient with infantile Canavan disease.
Zaki OK; El Abd HS; Mohamed SA; Zayed H
Metab Brain Dis; 2016 Jun; 31(3):573-7. PubMed ID: 26613958
[TBL] [Abstract][Full Text] [Related]
17. An atypical case of Canavan disease with stroke-like presentation.
Delaney KE; Kralik SF; Hainline BE; Golomb MR
Pediatr Neurol; 2015 Feb; 52(2):218-21. PubMed ID: 25497124
[TBL] [Abstract][Full Text] [Related]
18. Suppressing N-Acetyl-l-Aspartate Synthesis Prevents Loss of Neurons in a Murine Model of Canavan Leukodystrophy.
Sohn J; Bannerman P; Guo F; Burns T; Miers L; Croteau C; Singhal NK; McDonough JA; Pleasure D
J Neurosci; 2017 Jan; 37(2):413-421. PubMed ID: 28077719
[TBL] [Abstract][Full Text] [Related]
19. Are astrocytes the missing link between lack of brain aspartoacylase activity and the spongiform leukodystrophy in Canavan disease?
Baslow MH; Guilfoyle DN
Neurochem Res; 2009 Sep; 34(9):1523-34. PubMed ID: 19319678
[TBL] [Abstract][Full Text] [Related]
20. Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system.
Matalon R; Rady PL; Platt KA; Skinner HB; Quast MJ; Campbell GA; Matalon K; Ceci JD; Tyring SK; Nehls M; Surendran S; Wei J; Ezell EL; Szucs S
J Gene Med; 2000; 2(3):165-75. PubMed ID: 10894262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
